Phase 3 Stomach Cancer Trial, Recruiting NCT06793917 Sponsor: Fujian Cancer Hospital Condition: Stomach Cancer
Back to Stomach Cancer

Phase 3 Stomach Cancer Trial, Recruiting

NCT06793917
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with advanced, inoperable stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by tissue testing as a specific type called adenocarcinoma.
  • People aged between 18 and 70 years old.
  • People who are relatively well and able to carry out daily activities with little or no limitation (based on a standard performance scale scored 0 or 1).
  • People who have not had previous chemotherapy, radiotherapy, or immunotherapy for this cancer — though some exceptions may apply depending on the type and timing of any earlier treatment (confirm with trial site).
  • People with healthy bone marrow, liver, and kidney function, based on specific blood test results meeting the required levels.
  • People expected to live for at least 3 months.
  • People with a normal heart tracing (ECG) and no history of heart failure.
  • People with normal blood clotting function, based on specific test results.
  • People who agree to use contraception during the trial and for 8 weeks after the last dose of study medication.
  • People who have given written consent to take part in the trial.
  • People who have had, or can provide a tissue sample sufficient for, specific tumour marker tests (PD-L1, MMR/MSI, and HER2).

Who may not be able to join:

  • People who have had another cancer within the past three years, unless it was a specific low-risk type such as a certain skin cancer, early-stage cervical changes, or non-spreading prostate cancer.
  • People whose cancer has spread to the brain or spinal cord, including the membranes surrounding them.
  • People who are pregnant or breastfeeding.
  • People with a serious wound, ulcer, or bone fracture that has not healed.
  • People with significant heart problems, such as unstable chest pain, moderate-to-severe heart failure, or a heart attack within the past 6 months.
  • People who have had a stroke within the past 6 months.
  • People with significant disease affecting the blood vessels in the arms or legs.
  • People who are HIV-positive, or who have active hepatitis B or C.
  • People who are unlikely to be able to follow the study procedures or attend follow-up appointments.
  • People whose overall health condition, in the opinion of the treating doctor, makes participation in a clinical trial unsafe.
  • People whose tumour tests show a particular protein marker (HER2-positive) at levels that meet a specific threshold (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Rong bo Lin, bachelor, Fujian Cancer Hospital

Phone: 13705919382

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Fujian Cancer Hospital
Registry
ClinicalTrials.gov
Start date
7 June 2025
Est. completion
1 April 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

progression free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov